Leukemic stem cell frequency: a strong biomarker for clinical outcome in acute myeloid leukemia.

ABSTRACT:

Introduction

Treatment failure in acute myeloid leukemia is probably caused by the presence of leukemia initiating cells, also referred to as leukemic stem cells, at diagnosis and their persistence after therapy. Specific identification of leukemia stem cells and their discrimination from normal hematopoietic stem cells would greatly contribute to risk stratification and could predict possible relapses.

Results

For identification of leukemic stem cells, we developed flow cytometric methods using leukemic stem cell associated markers and newly-defined (light scatter) aberrancies. The nature of the putative leukemic stem cells and normal hematopoietic stem cells, present in the same patient's bone marrow, was demonstrated in eight patients by the presence or absence of molecul

SUBMITTER: Terwijn M 

PROVIDER: S-EPMC4171508 | biostudies-literature | 2014

REPOSITORIES: biostudies-literature